President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...

Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused ...

UBS downgraded Novo Nordisk to ‘Neutral’ from ‘Buy’ with a price target of DKK 340 ($52.59), down from DKK 600. The new price target still implies a near 9% upside to the stock’s closing price on ...

In June, Hims & Hers’ stock dropped over 30% following the breakdown of a brief partnership with Novo Nordisk. The ...